Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein Sells 28,390 Shares

Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein sold 28,390 shares of the company’s stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $80.90, for a total transaction of $2,296,751.00. Following the transaction, the chief financial officer now owns 155,506 shares of the company’s stock, valued at $12,580,435.40. This represents a 15.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Sara Bonstein also recently made the following trade(s):

• On Friday, January 10th, Sara Bonstein sold 1,066 shares of Insmed stock. The shares were sold at an average price of $63.72, for a total transaction of $67,925.52.
• On Tuesday, January 7th, Sara Bonstein sold 3,470 shares of Insmed stock. The shares were sold at an average price of $65.70, for a total transaction of $227,979.00.

Insmed Price Performance

NASDAQ INSM opened at $79.95 on Friday. The stock has a market capitalization of $14.30 billion, a P/E ratio of -14.41 and a beta of 1.11. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The business’s fifty day moving average is $72.79 and its two-hundred day moving average is $73.10. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $82.04.

Institutional Investors Weigh In On Insmed

A number of institutional investors and hedge funds have recently modified their holdings of INSM. Dimensional Fund Advisors LP acquired a new position in shares of Insmed in the 2nd quarter valued at $810,000. Truist Financial Corp acquired a new stake in Insmed during the 2nd quarter worth about $413,000. Park Avenue Securities LLC boosted its holdings in shares of Insmed by 28.5% in the third quarter. Park Avenue Securities LLC now owns 5,597 shares of the biopharmaceutical company’s stock worth $409,000 after buying an additional 1,240 shares during the period. GAMMA Investing LLC increased its position in shares of Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 224 shares in the last quarter. Finally, Tobam purchased a new position in shares of Insmed in the third quarter worth approximately $464,000.

Analyst Ratings Changes

INSM has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. Truist Financial reiterated a “buy” rating and set a $105.00 price target (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. Guggenheim raised their price target on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a report on Friday. Morgan Stanley upped their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, JPMorgan Chase & Co. raised their target price on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Friday. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, Insmed has an average rating of “Moderate Buy” and an average target price of $85.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.